Skip to main content
SpringerLink
Log in

News from ISPOR

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Bolin K, Gilljam H, Mörk AC, Lindgren B.The cost utility of varenicline in smoking cessation health prorammes in Sweden. Value in Health 10: A101, No. 3, May-Jun 2007

  2. Mauskopf J, Brogan A, Malmberg C, Hwang P.A Canadian cost-effectiveness analysis of darunavir for HIV infection in treatment experienced adults. Value in Health 10: A163 (plus poster) abstr. PIN14, No. 3, May-Jun 2007

  3. Redekop WK, Nuijten MJC.A cost-effectiveness study comparing ivabradine with standard care in stable angina pectoris in The Netherlands. Value in Health 10: A42 (plus poster) abstr. PCV20, No. 3, May-Jun 2007

  4. GARRISON LP, Cirrincione A, Giuliani G.Pharmacoeconomic analysis of treating advanced gastric cancer with capecitabine/cisplatin vs. 5-FU/cisplatin regimens in an Italian setting. Value in Health 10: A127 (plus poster) abstr. PCN14, No. 3, May-Jun 2007

  5. Sambrook JC, Levy AR, Osenenko K, Kindundu C, Barbeau M.Cost-effectiveness of lumiracoxib compared to celecoxib for the treatment of osteoarthritis in Canada. Value in Health 10: A117-A118 (plus poster) abstr. PAR3, No. 3, May-Jun 2007

  6. Contreras-Hernandez I, Mould-Quevedo J, Salinas-Escudero G, Silva A, Tapia-Valencia J, Davila-Loaiza G, Garduño-Espinosa J.A cost-effectiveness analysis model for the second line treatment of gastrointestinal stromal tumours in Mexico. Value in Health 10: A11, No. 3, May-Jun 2007

  7. Gajria KL, Wallenstein GV, Hagan MA.Cost-effectiveness of oral and transdermal contraceptive methods. Value in Health 10: A156 (plus poster) abstr. PIH3, No. 3, May-Jun 2007

  8. Wilson EC, Jayne DR, Dellow E, Fordham RJ.The cost-effectiveness of mycophenolate mofetil as first-line therapy in active lupus nephritis. Value in Health 10: A105-A106 (plus poster) abstr. PUK12, No. 3, May-Jun 2007

  9. Fonseca M, Araujo G.Cost effectiveness of the use of infliximab compared to other biological agents in the systemic treatment of moderate to severe psoriasis. Value in Health 10: A99 (plus poster) abstr. PSK1, No. 3, May-Jun 2007

  10. Windmeijer F, Brown J, Novick D, HONG J, Knapp M, Kontodimas S, Ratcliffe M, SOHO Study Group.36-Month cost-utility analysis of antipsychotic treatments in patients with schizophrenia in the PAN-European Soho (Schizophrenia Outpatient Health Outcomes) Study. Value in Health 10: A78-A79 (plus poster) abstr. PMH24, No. 3, May-Jun 2007

  11. Ikeda S, Kobayashi M.Cost-effectiveness analysis of palivizumab for respiratory syncytial virus infection in high-risk infants in Japan. Value in Health 10: A170 (plus poster) abstr. PIN35, No. 3, May-Jun 2007

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

News from ISPOR. Pharmacoecon. Outcomes News 531, 6–7 (2007). https://doi.org/10.2165/00151234-200705310-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705310-00011

Keywords

Search

Navigation